You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,696,291


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,696,291
Title: Synthetic HIV gag genes
Abstract:Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through stimulation of neutralizing antibody and cell-mediated immunity.
Inventor(s): Shiver; John W. (Doylestown, PA), Freed; Daniel C. (Limerick, PA), Davies; Mary Ellen (Norristown, PA), Liu; Margaret A. (Rosemont, PA), Perry; Helen C. (Lansdale, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/974,702
Patent Claims:1. A synthetic polynucleotide encoding a HIV gag antigen, said polynucleotide comprising codons optimized for expression in a mammalian host as set forth in the IIIV gag open reading frame of SEQ ID NO:1.

2. The synthetic polynucleotide of claim 1, comprising the nucleotide sequence as set forth in SEQ ID NO:1.

3. The synthetic polynucleotide of claim 1, which consists of the nucleotide sequence from nucleotide 10 through nucleotide 1512 as set forth in SEQ ID NO:1.

4. A DNA plasmid vaccine vector comprising a polynucleotide sequence encoding a HIV gag antigen, said polynucleotide sequence comprising codons optimized for expression in a mammalian host, said codons as set forth in the HIV gag open reading frame of SEQ ID NO:1.

5. The DNA plasmid vaccine vector of claim 4 which comprises the polynucleotide sequence as set forth in SEQ ID NO:1.

6. The DNA plasmid vaccine vector of claim 4 which consists of the polynucleotide sequence encoding the HIV gag open reading frame from nucleotide 10 through nucleotide 1512 as set forth in SEQ ID NO:1.

7. A pharmaceutical formulation comprising the DNA plasmid vaccine vector of claim 4.

8. The DNA plasmid vaccine vector of claim 4 which comprises an operable CMV immediate-early promoter and CMV intron A 5' to the polynucleotide sequence encoding a HIV gag antigen.

9. The DNA plasmid vaccine vector of claim 4, comprising: a) an operable CMV immediate-early promoter and CMV intron A; b) a tPA signal sequence 3' to the CMV immediate-early promoter/CMV intron A; and, c) the polynucleotide sequence encoding a HIV gag antigen 3' to the tPA signal sequence.

10. A pharmaceutical formulation comprising the DNA plasmid vaccine vector of claim 9.

11. The DNA plasmid vaccine of claim 8 which further comprises an operable BGH termination sequence at the 3' end of the polynucleotide sequence encoding a HIV gag antigen.

12. A pharmaceutical formulation comprising the DNA plasmid vaccine vector of claim 11.

13. The DNA plasmid vaccine of claim 9 which further comprises an operable BGH termination sequence at the 3' end of the polynucleotide sequence encoding a HIV gag antigen.

14. A pharmaceutical formulation comprising the DNA plasmid vaccine vector of claim 13.

15. A method of inducing an immune response against human immunodeficiency virus in a mammalian host which comprises introducing a pharmaceutical formulation into said mammalian host, wherein said pharmaceutical formulation comprises a DNA plasmid vaccine vector comprising a polynucleotide sequence encoding a HIV gag antigen, said polynucleotide sequence further comprising codons optimized for expression in a mammalian host, said codons as set forth in the HIV gag open reading frame of SEQ ID NO:1.

16. The method of claim 15 wherein said codons are optimized codons as set forth into HIV gag open reading frame of SEQ ID NO:1.

17. The method of claim 15 wherein said DNA plasmid vaccine vector comprises an operable CMV immediate-early promoter and CMV intron A 5' to the polynucleotide sequence encoding a HIV gag antigen.

18. The method of claim 15 wherein said DNA plasmid vaccine vector comprises: a) an operable CMV immediate-early promoter with the CMV intron A; b) a tPA signal sequence 3' to the CMV immediate-early promoter and CMV intron A; and, c) the polynucleotide sequence encoding a HIV gag antigen 3' to the tPA signal sequence.

19. The method of claim 17 wherein the DNA plasmid vaccine further comprises an operable BGH termination sequence at the 3' end of the polynucleotide sequence encoding a HIV gag antigen.

20. The method of claim 18 wherein the DNA plasmid vaccine further comprises an operable BGH termination sequence at the 3' end of the polynucleotide sequence encoding a HIV gag antigen.

Details for Patent 6,696,291

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2017-02-07
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2017-02-07
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2017-02-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.